The countries that TruScreen is currently available in are highlighted in purple on the map, click on a region to learn more. If the country you are interested in is not highlighted, please feel free to contact us for information on a distributor in your region. 

×
Region:

Turkey

Screening Population:

21,359,903

Distributor:

Gelisim Medikal Limited

Joined 2016

Cervical cancer ranks as the 13th most frequent cancer among women in Turkey and the 4th most frequent cancer among women between 15 and 44 years of age.

http://www.gelisimmedikal.com/tr_TR/kubragokmen@gelisimmedikal.com

Region:

China

Screening Population:

402,269,064

Distributor:

Siweixiangtai Tech Ltd Co.

Joined 2014

China is TruScreen’s most established market. It accounts for over 20% of cervical cancer diagnoses worldwide. TruScreen has been involved in several large-scale evaluation trials with public governing bodies, screening over 18,000 women.

www.bjswxt.com13366592526@163.com

Region:

Mexico

Screening Population:

33,009,896

Distributor:

Sunbird S.A. de C.V.

Joined 2020

Mexico is TruScreen’s entry point into South America, with cervical cancer being the third most common cancer in women in the region. TruScreen has been present in Mexico since 2015.

https://sunbirdict.com/fjcamargo@me.com

Region:

Indonesia

Screening Population:

68,377,584

Distributor:

PT Hospi Niaga Utama

Joined 2018

Cervical cancer ranks as the 2nd most frequent cancer among women in Indonesia. In 2018 TruScreen was granted approval, by Department Kesehatan RI, for use and sale in the country.

https://www.hospiniaga.com/yanuar.kristian@hospiniaga.com

Region:

Saudi Arabia

Screening Population:

7,582,946

Distributor:

Bettalife Trading FZC

Joined 2018

Cervical cancer ranks as the 9th most frequent cancer among women in Saudi Arabia. More than 40% of cervical cancer cases are diagnosed at advanced stages due the absence of a routine cervical screening program.

https://www.bettalife.me/index.php/en/

Region:

Kuwait

Screening Population:

655,658

Distributor:

Bettalife Trading FZC

Joined 2018

Kuwait is TruScreen’s second territory in it’s Pan-Arab agreement with BettaLife. Cervical cancer is the 3rd most common cancer in women aged 15 to 44 years in Kuwait.

http://bettalife.me/test2/index.php/en/

Region:

Israel

Screening Population:

1,945,108

Distributor:

Metis Aesthetic Marketing 2017 Ltd

Joined 2019

Cervical cancer is the 4th most frequent cancer for women aged 15 to 44 years in Israel. TruScreen is registered with the Israeli Ministry of Health.

https://metis.co.il

Region:

Russia

Screening Population:

42,712,801

Distributor:

JSC IMSystems

Joined 2019

Cervical Cancer is the fourth most common cancer for women in Russia. TruScreen has been present in Russia since 2015, and after bringing on a new distribution partner in early 2019 sales in the region have grown.

https://www.truscreen.ru/ 

Region:

Czech Republic

Screening Population:

2,910,522

Distributor:

Aspironix Group s.r.o

Joined 2020

Cervical cancer ranks as the 12th most common female cancer in Czech Republic and is the 8th leading cause of cancer related deaths in women.

https://www.aspironix.com/

Region:

Slovakia

Screening Population:

1,572,199

Distributor:

Aspironix Group s.r.o

Joined 2020

Cervical cancer ranks as the 6th leading cause of female cancer in Slovakia, it is the 2nd most common cancer in women ages 15 to 44 years.

https://www.aspironix.com/

Region:

Poland

Screening Population:

10,878,997

Distributor:

Aspironix Group s.r.o

Joined 2020

Cervical cancer is the 4th most common cancer in women ages 15 to 44 years in Poland and is the 7th most frequent cancer among women in general.

https://www.aspironix.com/

Region:

Vietnam

Screening Population:

27,279,446

Distributor:

Gorton Health Service Pty Ltd

Joined 2016

Cervical cancer ranks as the 7th most common cancer for women in Vietnam. TruScreen has been in Vietnam since 2016. In 2020 TruScreen received Ministry of Health approval for us in leading Hanoi Obstetrics and Gynaecology Hospital.

http://truscreen.com.vn/vi/

Region:

Cambodia

Screening Population:

4,197,298

Distributor:

Gorton Health Service Pty Ltd

Joined 2019

Cervical cancer is the 2nd most common cancer for women in Cambodia.

ian.gortonghs@gmail.com

Region:

Malaysia

Screening Population:

8,023,056

Distributor:

Gorton Health Service Pty Ltd

Joined 2019

Cervical cancer is the 2nd most frequent cancer for women aged between 15 and 44 years in Malaysia, and the 3rd most common cancer for women overall in the country.

ian.gortonghs@gmail.com

Region:

Thailand

Screening Population:

20,650,154

Distributor:

Gorton Health Service Pty Ltd

Joined 2019

Cervical cancer is 2nd most prevalent cancer for women in Thailand.

ian.gortonghs@gmail.com

Region:

India

Screening Population:

318,289,357

Distributor:

Khandelwal Laboratories Pvt. Ltd

Joined 2017

India accounts for one-quarter of the global burden. Cervical cancer is the second leading cause of cancer death in women in the country. TruScreen has been present in the region since 2017.

http://www.khandelwallab.com/default.htmsanjeev@khandelwallab.com

Region:

Zimbabwe

Screening Population:

2,698,797

Distributor:

Southern Skies Medical Pty Ltd

Joined 2018

Cervical cancer is the most common cancer among women in Zimbabwe. In 2018 TruScreen partnered with Zimbabwe’s National Aids Council (NAC) for a national cervical screening project.

ndoro.herbert@gmail.com

Region:

Serbia

Screening Population:

1,924,839

Distributor:

MPG d.o.o Beograd

Joined 2020

Cervical cancer ranks as the 4th most frequent cancer among women in Serbia, and the 2nd most frequent cancer among women between 15 and 44 years of age.

office@mpgdoo.rs

Region:

Montenegro

Screening Population:

163,131

Distributor:

MPG d.o.o Beograd

Joined 2020

Cervical cancer is the 4th most common female cancer in Montenegro, and the second most frequent cancer among women between 15 and 44 year of age.

office@mpgdoo.rs

Region:

Macedonia

Screening Population:

600,552

Distributor:

MPG d.o.o Beograd

Joined 2020

Cervical cancer is the 6th most frequent cancer among women in Macedonia.

office@mpgdoo.rs

Region:

Bosnia

Screening Population:

1,148,239

Distributor:

MPG d.o.o Beograd

Joined 2020

Cervical cancer is the 2nd most common cancer for women in Bosnia.

office@mpgdoo.rs

Our focus markets

After in-depth market study and evaluation, we have determined that the optimal commercialisation strategy is to first penetrate low-and-middle-income countries (LMICs) where no large scale cervical cancer screening programs and infrastructure are in place.

In parallel to this commercial strategy, we are obtaining the academic endorsement of key opinion leaders to assist in both current and future global marketing efforts.

There are two main market segments for each country – a) population-based screening and b) general clinical use in hospitals and clinics. The or4ganised screening programs are mainly funded through Government procurement programmes equating to large screening populations but in many countries, there are also significant NGO and Corporate funded screening programs.

The government screening programmes are the key to success for TruScreen in developing markets. We nominate distributors based on their ability to demonstrate a solid relationship with Key Opinion Leaders and strong Government contacts.

Concurrent with our efforts to maximise the sales of TruScreen in our primary target markets we are also engaged in the process of selecting the second phase of target markets and identifying suitable distributors to work with us in those markets. This process has been initiated in the Middle East, Central and Eastern Europe, and Africa.

The global market potential for TruScreen is significant. At saturation, hundreds of millions of women could benefit from this accurate and inexpensive cervical cancer screening method.

However, the single most important potential benefit from the global commercialisation of TruScreen is the saving of human life.